Top 10 Oncology CROs for Biotech & Pharma in 2026
Choosing the right oncology contract research organization can have a major impact on study design, timelines, data quality, patient recruitment, and ultimately the success of a cancer drug development program.
So, what are some of the top oncology CROs to consider in 2026?
CROaccess’s 2026 oncology CRO shortlist includes Champions Oncology, Crown Bioscience, Allucent, Linical, Imaging Endpoints, Southern Research, Altogen Labs, InSphero, Evotec, and Sapient Bioanalytics.
These organizations cover different parts of oncology development, including preclinical tumor models, immuno-oncology, clinical trials, imaging, biomarker discovery, multi-omics, drug discovery, and translational research.
There is no single “best oncology CRO” for every program. The right partner depends on your development stage, therapeutic modality, tumor type, geographic requirements, study design, and internal capabilities.
This guide compares 10 oncology CROs available through CROaccess and highlights the types of projects each may be best suited for.
Top Oncology CROs at a Glance
| Oncology CRO | Best Fit |
|---|---|
| Champions Oncology | Patient-derived oncology models and translational oncology |
| Crown Bioscience | Large-scale preclinical oncology and immuno-oncology |
| Allucent | Clinical oncology programs for small and mid-sized biopharma |
| Linical | Global and early-phase oncology clinical trials |
| Imaging Endpoints | Oncology imaging and imaging endpoints |
| Southern Research | Preclinical oncology and radiopharmaceutical research |
| Altogen Labs | Xenograft and focused preclinical oncology studies |
| InSphero | 3D tumor models and human-relevant in vitro oncology |
| Evotec | Integrated oncology drug discovery |
| Sapient Bioanalytics | Oncology biomarkers, proteomics, and multi-omics |
How We Selected These Oncology CROs
This list is designed to help biotech and pharmaceutical teams identify potential partners rather than declare one provider universally better than another.
- Depth of oncology specialization
- Range of relevant services
- Preclinical or clinical capabilities
- Translational research capabilities
- Specialized technology or model systems
- Suitability for different stages of oncology drug development
- Current presence within the CROaccess network
Sponsors should perform their own scientific, operational, quality, regulatory, and commercial diligence before selecting a CRO.
1. Champions Oncology
Best for: Patient-derived tumor models and translational oncology
View Champions Oncology on CROaccess
Champions Oncology is a specialized oncology CRO with a strong focus on preclinical and translational oncology. Its CROaccess profile highlights tumor growth inhibition studies, patient-derived xenograft models, flow cytometry, FACS cell sorting, tumor immunophenotyping, and immune-cell characterization.
- Patient-derived xenograft studies
- Tumor growth inhibition studies
- Immuno-oncology programs
- Translational oncology
- Biomarker studies
- Hematologic malignancies
- Ex vivo screening
2. Crown Bioscience
Best for: Broad preclinical oncology model selection
View Crown Bioscience on CROaccess
Crown Bioscience focuses heavily on translational oncology and immuno-oncology drug discovery and development. Its broad oncology model portfolio can be useful for sponsors that need to compare multiple model systems before committing to a preclinical strategy.
- PDX studies
- CDX studies
- Immuno-oncology
- Humanized mouse models
- Organoid studies
- Efficacy testing
- Resistance modeling
- Biomarker analysis
3. Allucent
Best for: Clinical oncology development for small and mid-sized biopharma
Allucent is a global full-service clinical CRO focused particularly on small and mid-sized biopharmaceutical companies. Its CROaccess profile includes clinical development, regulatory strategy, clinical pharmacology, biometrics, safety, pharmacovigilance, medical writing, and global trial operations.
- Phase I–III oncology trials
- Small and mid-sized biotech sponsors
- Adaptive trial designs
- Biomarker-driven trials
- Immunotherapies
- Cell and gene therapies
- Regulatory strategy
4. Linical
Best for: Early-phase and global oncology trials
Linical is a global CRO headquartered in Japan with oncology as one of its key therapeutic specialties. The CROaccess profile highlights oncology clinical trials, regulatory experience in Asian markets, clinical operations, data management, biostatistics, and regulatory affairs.
- Early-phase oncology trials
- Phase I and Phase II studies
- Rare cancers
- Global oncology development
- Asia-Pacific clinical programs
- Immunotherapy studies
5. Imaging Endpoints
Best for: Imaging-intensive oncology clinical trials
View Imaging Endpoints on CROaccess
Oncology trials frequently rely on imaging to assess disease burden, tumor response, progression, and therapeutic effectiveness. Imaging Endpoints specializes in clinical trial imaging and has extensive oncology experience.
- Oncology imaging endpoints
- Central imaging review
- Radiology-heavy clinical trials
- Response assessment
- Nuclear medicine
- Imaging biomarker development
6. Southern Research
Best for: Preclinical oncology and radiopharmaceutical development
View Southern Research on CROaccess
Southern Research offers oncology research capabilities spanning drug discovery and preclinical development, including tumor biology, immunology, radiopharmacology, tumor microenvironment analysis, spatial transcriptomics, tumor kinetics, and hematologic cancer research.
- Preclinical oncology
- Radiopharmaceutical development
- Biodistribution studies
- Tumor microenvironment research
- Hematological cancer research
- Xenograft studies
- Syngeneic models
7. Altogen Labs
Best for: Focused xenograft and preclinical oncology studies
View Altogen Labs on CROaccess
Altogen Labs provides preclinical research services with a substantial emphasis on xenograft oncology models, cell-based assays, toxicology, gene-expression analysis, and related preclinical services.
- Focused xenograft efficacy studies
- Solid-tumor models
- Anti-tumor activity testing
- Cell-based assays
- Oncology pharmacology
- Small preclinical programs
8. InSphero
Best for: 3D tumor spheroids and human-relevant in vitro oncology models
InSphero develops advanced 3D cell-based systems that can be used for oncology research and therapeutic screening, including patient-derived primary tumor spheroid models and tumor-immune co-culture systems.
- 3D tumor spheroids
- Patient-derived tumor models
- Tumor-immune co-culture
- Immuno-oncology screening
- Human-relevant in vitro models
- High-throughput oncology screening
9. Evotec
Best for: Integrated oncology drug discovery
Evotec provides integrated drug discovery and development capabilities across multiple therapeutic areas, including oncology and immuno-oncology, with support for target identification, target validation, biomarker strategy, assay development, and preclinical candidate development.
- Oncology drug discovery
- Target identification and validation
- Immuno-oncology
- Precision oncology
- Biomarker strategy
- Integrated discovery programs
10. Sapient Bioanalytics
Best for: Oncology biomarkers and multi-omics
View Sapient Bioanalytics on CROaccess
Sapient Bioanalytics is a multi-omics CRO specializing in biomarker discovery. Its CROaccess profile highlights metabolomics, lipidomics, proteomics, bioinformatics, patient stratification, drug efficacy monitoring, and precision medicine applications.
- Oncology biomarker discovery
- Proteomics
- Metabolomics
- Lipidomics
- Patient stratification
- Precision oncology
- Target discovery
Which Oncology CRO Is Best for Your Project?
The best oncology CRO depends primarily on what problem you need the CRO to solve.
Need patient-derived tumor models? Champions Oncology or Crown Bioscience may be strong starting points.
Need a clinical oncology CRO? Allucent or Linical may be more appropriate.
Need oncology imaging? Consider Imaging Endpoints.
Need radiopharmaceutical or broad preclinical work? Southern Research may fit the program.
Need a focused xenograft study? Altogen Labs may be worth evaluating.
Need advanced 3D tumor models? Consider InSphero.
Need an integrated discovery partner? Evotec may be appropriate.
Need proteomics, biomarkers, or multi-omics? Sapient Bioanalytics may be particularly relevant.
How to Choose an Oncology CRO
1. Oncology Experience
Ask whether the CRO has experience with your tumor type, therapeutic modality, development stage, and proposed endpoints. General oncology experience is useful, but indication-specific experience can matter even more.
2. Scientific Capabilities
Determine whether the CRO already has the models, assays, equipment, expertise, and validated workflows required for your project.
3. Development Stage
A CRO that is excellent for preclinical xenograft studies may not be the right organization to manage a multinational Phase III oncology trial. Make sure the provider’s core capabilities match your current stage.
4. Operational Fit
Evaluate communication, project management, timelines, data access, reporting, quality systems, and escalation procedures.
5. Proposal and Budget
Compare more than headline pricing. Review assumptions, scope exclusions, pass-through expenses, change-order policies, timelines, deliverables, and what happens if the study changes.
Find Oncology CROs Through CROaccess
Finding an oncology CRO does not have to begin with a Google search and dozens of individual contact forms.
CROaccess helps life-science teams discover CROs, compare capabilities, and identify providers aligned with specific project requirements.
Frequently Asked Questions About Oncology CROs
What is an oncology CRO?
An oncology CRO is a contract research organization that provides outsourced research or clinical development services for cancer therapeutics. Services can include drug discovery, tumor models, efficacy studies, biomarker analysis, imaging, toxicology, clinical trial operations, biostatistics, regulatory support, and patient recruitment.
What are some of the top oncology CROs?
Oncology CROs to consider include Champions Oncology, Crown Bioscience, Allucent, Linical, Imaging Endpoints, Southern Research, Altogen Labs, InSphero, Evotec, and Sapient Bioanalytics. The best choice depends on whether the project requires preclinical models, clinical trial execution, imaging, biomarkers, or another specialized capability.
Which CRO is best for preclinical oncology?
Champions Oncology and Crown Bioscience are particularly relevant for oncology model systems, while Southern Research, Altogen Labs, InSphero, and Evotec offer different types of preclinical oncology capabilities.
Which CRO is best for oncology clinical trials?
Allucent and Linical are two options within the CROaccess network with substantial clinical oncology capabilities. The right choice depends on trial phase, indication, geography, therapeutic modality, and required services.
What should I look for when choosing an oncology CRO?
Evaluate therapeutic-area experience, study-stage experience, model and assay capabilities, regulatory expertise, project management, data quality, geography, timelines, communication, and total study cost.
How much does an oncology CRO cost?
There is no standard oncology CRO price. Costs vary widely based on the type of study, model, number of subjects or animals, sites, endpoints, assays, regulatory requirements, geography, timelines, and level of CRO involvement.
How can I compare multiple oncology CROs?
Create a consistent project brief or RFP and provide the same requirements to each CRO. Compare scientific fit, relevant experience, proposed study design, timeline, team, assumptions, deliverables, pricing, and change-order terms. CROaccess can also help teams identify and compare relevant CRO partners.
Final Takeaway
There is no universal number-one oncology CRO. The strongest partner for a Phase I oncology trial may be very different from the strongest partner for a PDX efficacy study, imaging endpoint, tumor spheroid program, radiopharmaceutical study, or biomarker discovery project.
The best next step is to define the scientific requirements of your program first—and then evaluate CROs against those requirements.
